Memantin Abdi

Memantine, the active ingredient in Memantin Abdi, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, helping to improve cognition and functional abilities.

GNH USA supplies Memantin Abdi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers. Its distribution network ensures timely delivery and regulatory compliance across multiple regions.

Memantine is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting memory and cognition.

- Moderate to severe Alzheimer’s disease: Improves cognition, memory function, and daily living activities in patients with moderate to severe disease. - Mild to moderate Alzheimer’s disease (off‑label): May provide modest cognitive benefit when used early in disease progression. - Behavioral symptoms of Alzheimer’s disease: Can help reduce agitation, aggression, and other neuropsychiatric manifestations.

Memantine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (anaphylaxis, rash) - Hallucinations or psychosis

When prescribing memantine, clinicians should consider several safety and handling precautions. - Renal impairment: assess kidney function and adjust dose if necessary. - History of seizures: monitor closely for increased seizure activity. - Cardiovascular disease: use with caution in patients with unstable heart conditions. - Concurrent NMDA antagonists: avoid co‑administration to prevent additive neurotoxicity. - Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Memantine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Ketamine: additive NMDA blockade can cause severe central nervous system depression. - High‑dose aspirin: may heighten risk of dizziness and hypotension.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: memantine may enhance blood‑pressure‑lowering effects. - Anticholinergic drugs: may diminish cognitive benefits of memantine. - Diuretics: potential electrolyte disturbances require monitoring.